A combination of in silico and in vitro screening of many siRNA candidates led to identification of a lead sequence (named “C05C”; also referred to as “siRRM2B + 5”) which was shown to be a potent downregulator of RRM2 in cancer cells of various types and species and induced a concomitant antiproliferative effect in those cells [24]. Here, RRM2 is linked to cancer.